HRID Forms Scientific Advisory Board
/PRNewswire/ -- Nouveau Life Pharmaceuticals (soon to be changed from Hybrid Fuels, Inc.), (Pink Sheets: HRID) announced today the formation of its Scientific Advisory Board. The Board will provide clinical and strategic guidance to the Company for its nutraceutical product line.The Company is currently in the process of interviewing qualified candidates to participate on the Scientific Advisory Board and expects to make announcements this week regarding the initial selections.
"It is imperative that we have the input of innovative scientific leaders to help guide us during this high-growth stage of Nouveau Life product development. We are very pleased by the interest of seasoned scientific professionals to serve on the Board and look forward to their participation in our ongoing success," stated Ramiro Cadena, CEO of Hybrid Fuels, Inc.
The Company recently announced the introduction of Azul Instant™, an all-natural supplement for ED that provides the millions of men suffering from the condition with a safe alternative to prescription drugs. Developed by a team of experts, the Company's goal is to create the healthiest and most effective all-natural male enhancer ever formulated. Unlike pharmaceutical drugs such as Cialis, Viagra and Levitra, Azul Instant™, carries no dangerous side effects.
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today top-line results from the ORAL Scan Phase 3 study (A3921044) of tofacitinib (development code: CP-690550), formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor.